Sunhawk Vision Biotech (ROCO:7759) Beginning Cash Position: NT$401.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7759 Sunhawk Vision Biotech Inc ROCO:7759
20 GF Score
Price NT$30.50
! 1 Warning Sign
View Full Analysis

What is Sunhawk Vision Biotech Beginning Cash Position?

Sunhawk Vision Biotech ROCO:7759 +0.33% 20 Beginning Cash Position is NT$401.02 Mil as of Jun. 2026. GuruFocus rates ROCO:7759 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Sunhawk Vision Biotech's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$401.02 Mil.

Sunhawk Vision Biotech's quarterly Beginning Cash Position increased from Jun. 2025 (NT$111.40 Mil) to Dec. 2025 (NT$255.22 Mil) and increased from Dec. 2025 (NT$255.22 Mil) to Jun. 2026 (NT$401.02 Mil).

Sunhawk Vision Biotech's annual Beginning Cash Position increased from Dec. 2023 (NT$46.81 Mil) to Dec. 2024 (NT$175.07 Mil) but then declined from Dec. 2024 (NT$175.07 Mil) to Dec. 2025 (NT$111.40 Mil).

Sunhawk Vision Biotech Beginning Cash Position Related Terms

Sunhawk Vision Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Sunhawk Vision Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunhawk Vision Biotech Beginning Cash Position Chart

Sunhawk Vision Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 9.79 11.93 46.81 175.07 111.40

Sunhawk Vision Biotech Semi-Annual Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.07 112.77 111.40 255.22 401.02
ROCO:7759
20GF Score
Sunhawk Vision Biotech Inc ROCO:7759
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunhawk Vision Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$401.02 Mil mean?
Sunhawk Vision Biotech (ROCO:7759) has a Beginning Cash Position of NT$401.02 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sunhawk Vision Biotech and its competitors.
Is Sunhawk Vision Biotech's Beginning Cash Position too high?
Sunhawk Vision Biotech's current Beginning Cash Position is NT$401.02 Mil. Overall, Sunhawk Vision Biotech has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Sunhawk Vision Biotech's Beginning Cash Position compare to VRTX and REGN?
Sunhawk Vision Biotech's Beginning Cash Position of NT$401.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sunhawk Vision Biotech and its competitors. Sunhawk Vision Biotech's current Beginning Cash Position is NT$401.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunhawk Vision Biotech stock overvalued right now?
Sunhawk Vision Biotech (ROCO:7759) has a current Beginning Cash Position of NT$401.02 Mil. The current Beginning Cash Position is NT$401.02 Mil. Sunhawk Vision Biotech's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Sunhawk Vision Biotech (ROCO:7759), the current Beginning Cash Position is NT$401.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunhawk Vision Biotech Business Description

Address No. 6 Siwei 3rd Road, 17th Floor, Room A1, Lingya District, Kaohsiung, TWN
Sunhawk Vision Biotech Inc is a biotechnology company. The company is focused on developing new solutions for eye health and vision care. The company specializes in research and development of cutting-edge technologies aimed at treating and preventing ocular diseases. Their product portfolio includes products and services for curing dry eyes, myopia, and corneal erosion.
20GF Score

Get the complete analysis for ROCO:7759

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.50
Price